ClinicalTrials.gg
CompletedNCT01857596PURPLEUpdated Oct 28, 2014

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety

A Phase 1/2 interventional study of bupropion, Lorexys low-dose, Lorexys moderate-dose in Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined) and Sexual Interest/Arousal Disorder (DSM-5 Defined), sponsored by S1 Biopharma, Inc.. Completed at 2 sites in United States. Open to female participants aged 25 Years to 50 Years. Per ClinicalTrials.gov, last updated 2014-10-28.

Sponsored by S1 Biopharma, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
25 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.

Enrollment
46th of 59
30 · median 196
Started
2013
with 2 others
Phase 1/2
2 of 62
1 open now
Registered
38th of 62
by date

Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 46th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2013, is one of 2 in phase 1/2, and was the 38th registered.

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

Browse Sexual Dysfunctions, Psychological studies →

Open to participants now

3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 25 Years to 50 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Sexual Dysfunctions, Psychological with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate whether Lorexys is effective and safe to treat premenopausal women who have lost their sexual desire to a distressing degree.

Read the detailed description

Women are diagnosed with Hypoactive sexual desire disorder (HSDD) if they experience chronic loss of desire for sex together with significant distress or interpersonal difficulties due to this lack of desire. HSDD can have a serious effect on emotional well-being and interpersonal relationships.

There are no U.S. Food and Drug Administration-approved treatments for HSDD. Off-label treatments include testosterone, which is not always effective and can be accompanied by side effects such as excess hair growth, acne, and decreases in high-density lipoprotein (HDL) cholesterol levels.

Research in laboratory animals and clinical observations in humans suggest that re-balancing chemical messengers in the brain may stimulate sexual desire. S1 Biopharma's Lorexys® is a novel use fixed-dose combination (FDC) in an oral pill. Lorexys® combines two agents intended to restore balance to the brain's centers that control sexual function. Such effects are hoped to help women with HSDD.

The compound is Phase 2-ready without prior trials (Phase I safety studies) because the two agents have often been used together; individually, they are FDA-approved for treating other disorders (depression, for example), and in a large US survey, the two were taken together in about 23% of patients who were prescribed one of the two agents.

This research study requires subjects to take three different study medications for four weeks each, with at least a one-week "wash-out" period after each, and to report on rating scales how they feel. The medication is open-label (the subjects can see which medication they are receiving). That should not interfere with the evaluations or cause a big "placebo effect" because only a low proportion of women with HSDD have responded to a placebo in prior research studies of other compounds when using the same measures of efficacy.

Participation lasts 16 weeks, with 8 clinic visits. A weekly, but no daily, self-rating is required between visits.

03

Conditions studied

  • Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined)
  • Sexual Interest/Arousal Disorder (DSM-5 Defined)

Keywords

  • Female Sexual Dysfunction
  • Hypoactive Sexual Desire Disorder
  • Sexual Interest/Arousal Disorder
  • Lorexys
  • Premenopausal female health
04

Who can participate

Ages eligible
25 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 25 to 50 and still having regular menstrual periods. Women with intact ovaries are classified as premenopausal for this study, even if they have had a hysterectomy. Women who have had both ovaries removed, even if under age 50 and with an intact uterus, are not acceptable for this study.
  2. In a stable, monogamous, communicative, reasonably amicable relationship for at least one year
  3. Meets criteria for Generalized Acquired Hypoactive Sexual Desire Disorder and HSDD is her main sexual disorder
  4. Over the prior month, didn't respond to sexual initiations by partner
  5. At screen and baseline, low or no and infrequent or rare desire for sex
  6. At screen, has sexual distress as per FSDS-R score
  7. Otherwise healthy physically and mentally. Minor chronic conditions not affecting sexual function are allowed. Side effects from any continuing concomitant medications must be mild and stable or nil.
  8. Not pregnant or lactating for six months; using medically reliable , i.e., diaphragm or (male or female) condom and spermicide, IUD, tubal sterilization, hormonal contraception (oral, vaginal, or implant), or (if the investigator finds the patient credibly monogamous) vasectomy of male partner.
  9. Gives for and is willing to undergo all of the scheduled evaluations
  10. Prompt for screening and baseline visits, is cooperative, and takes reasonable directions without excessive explanations
  11. Her sexual partner is in a monogamous relationship with her, is sexually unimpaired (erectile dysfunction allowed only if adequately treated), and is available to her at least half of the time (in days per week).

Exclusion criteria

Exclusion Criteria:

  1. Masturbates more than once a month.
  2. Sexual aversion or sexual pain disorder
  3. Chronic conditions that may reasonably be expected to be unstable or to affect sexual function (e.g., gastrointestinal bleeding, diabetes, frequent asthma, Major Depressive or anxiety disorder, history within the prior 6 months of suicidality or drug abuse; history of breast, cervical, uterine, ovarian or other systemic cancer).
  4. (a standard ratio of weight to height) over 35.0 (obese)
  5. Requires , CYP 2B6, or CYP 2D6 strong inhibitor or inducer drugs
  6. Takes any sex hormone other than an approved hormonal
  7. Takes an antiepileptic/mood stabilizer, antipsychotic, antidepressant, anti-anxiety, or hypnotic drug or has a history of allergic reaction to such drugs
  1. Drinks more than 7 alcoholic drinks per week (12-oz beer, 4-oz wine, 1 ½ oz liquor etc) 10. Drinks more than 6 cups of coffee or tea per day 11. History of seizures 12. Long syndrome (QTc \<=480 msec), other significant cardiovascular disease 13. moderate or severe dysfunction of the liver (any LFT >=3x ) or renal dysfunction (BUN > 30 or Cr >2.0) 14. Uses sedating antihistamines or prescription sedatives 15. History of blood clots or abnormal bleeding tendencies, including daily use of medications adversely affecting coagulation, e.g., NSAIDs, systemic , or >81 mg aspirin daily.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Bupropion -> Lorexys LO -> Lorexys HI

    Crossover with all on positive comparator,lower-dose Lorexys,higher-dose Lorexys

    Drug: bupropion, Lorexys low-dose, Lorexys moderate-dose

Interventions

  • Drugbupropion, Lorexys low-dose, Lorexys moderate-dose

    Lorexys is a proprietary fixed-dose combination of two agents

    Also known as: Lorexys is bupropion plus trazodone, Lorexys lower-dose is 225 mg per day., Lorexys moderate-dose is 450 mg per day.

06

What researchers measure

Primary outcomes

  1. Change in Desire domain of the Female Sexual Function Index

    One item asks how often the subject feels sexual desire, and another item asks how much she feels desire. One of five answers must be checked for each item.

    Time frame: Four weeks after baseline

Secondary outcomes

  1. Change in Female Sexual Distress Scale-Revised

    The subject self-rates 13 negative feelings, such as frustration, bother, and unhappiness, that may have occurred because of her sexual problems.

    Time frame: Four weeks after baseline

  2. Change in Side Effects Checklist - 24 item

    The subject self-rates how much (if any) she has been bothered by each of the 24 symptoms that have been commonly reported with similar drugs, such as headache, sleepy, and anxious, from "not at all" to "extremely."

    Time frame: 4 weeks after baseline

  3. Patient's Global Impression of Change

    Subject self-rates how much, if any, her sexual disorder has changed since starting the current study medication (worse, same, or 4 degrees of improvement)

    Time frame: 4 Weeks after baseline

  4. Change in blood pressure and pulse

    Blood pressure and pulse are taken lying and standing

    Time frame: Four weeks after baseline

  5. Change in 12-lead electrocardiogram

    An electrocardiogram is used to measure the regularity of the heartbeat and how well electrical impulses are transmitted through the heart

    Time frame: 15 weeks (end of last treatment) after screen

  6. Change in routine lab studies including pregnancy tests and screen for illicit drugs

    About two teaspoons of blood are drawn to measure blood cells and body chemistry, and to see if the patient has become pregnant or has taken unauthorized substances.

    Time frame: Screen (wk 0), end of treatment/new baseline (wks 6, 11, 15)

Other outcomes

  1. Change in Columbia Suicide Severity Rating Scale, Screen Version (6 items)

    Brief interview of 3-6 specified questions asking if the patient feels like, wants to, or plans to be dead

    Time frame: 4 weeks after baseline

07

Study locations

2 sites
  • Robert Taylor Segraves, MD, PhD
    Beachwood, Ohio 44122, United States
  • Molly Katz, MD
    Cincinnati, Ohio 45219, United States
08

References and documents

Publications

  • Moll JL, Brown CS. The use of monoamine pharmacological agents in the treatment of sexual dysfunction: evidence in the literature. J Sex Med. 2011 Apr;8(4):956-70. doi: 10.1111/j.1743-6109.2010.02190.x. Epub 2011 Jan 27. PubMed 21272265 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2013
First posted
May 20, 2013
Start
Apr 2013
Primary completionActual
Oct 2014
CompletionActual
Oct 2014
Last update
Oct 28, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01857596
Lead sponsor
S1 Biopharma, Inc.
Responsible party
Sponsor
First posted
May 20, 2013
Start date
Apr 2013
Primary completion
Oct 2014
Completion
Oct 2014
Last update
Oct 28, 2014

Study contacts

Robert T Segraves, MD, PhD
principal investigator · Levine, Risen & Associates, Inc.
Molly Katz, MD
principal investigator · Katz and Kade, Inc.
Robert E Pyke, MD, PhD
study director · Chief Medical Officer, S1 Biopharma, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion